Healthcare Industry News: Naproxen
News Release - July 10, 2007
Victory Pharma, Inc. Doubling U.S. Sales ForceSAN DIEGO and CARY, N.C., July 10 (HSMN NewsFeed) -- Victory Pharma, Inc. (Victory) announced today that it has initiated the hiring of additional sales representatives to further accelerate the growth of NAPRELAN®, its leading marketed pain product.
"As a result of the favorable promotional response to NAPRELAN, Victory is committed to continue its sales force expansion," states Mike Goolsby, Vice President of Sales. "Since Victory began promoting NAPRELAN in January 2007, product sales have more than doubled. The expansion will increase Victory's U.S. sales force two-fold, which will significantly increase the Company's ability to maximize the market potential of NAPRELAN and its other pain products. The market potential for NAPRELAN is significant given the void created by withdrawals of multiple COX-2 therapies."
In addition to its sales force expansion, Victory intends to secure additional co-marketing partners to extend promotion into physician specialties the Company's sales force will not reach.
NAPRELAN is the only once-a-day, formulation of Naproxen sodium. The unique, patent-protected formulation provides rapid onset of relief, while improving compliance for patients suffering from mild to moderate pain.
NAPRELAN (Naproxen sodium) Controlled Release Tablets are commercially available in 375 mg and 500 mg dosage strengths.
NAPRELAN Tablets use Elan's proprietary Intestinal Protective Drug Absorption System (IPDAS®) Technology. The tablet system combines an immediate release component with a sustained release component of microparticles that are widely dispersed, allowing absorption of the active ingredient throughout the gastrointestinal tract, providing convenient once-daily administration.
NAPRELAN Tablets are indicated for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis and acute gout. It is also indicated for the relief of mild to moderate pain and the treatment of primary dysmenorrhea.
Important Safety Information
NAPRELAN Tablets are contraindicated in patients with known hypersensitivity to Naproxen or Naproxen sodium. NAPRELAN Tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs). Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients.
Please see full prescribing information including BOXED warning regarding cardiovascular and gastrointestinal risks.
Full prescribing information for NAPRELAN Tablets may be obtained in the U.S. from Victory Pharma Professional Services by calling toll free 866-427-6819 or on Victory Pharma's Web site at http://www.victorypharma.com
About Victory Pharma, Inc. Victory Pharma, Inc. is a privately held, specialty pharmaceutical company, headquartered in San Diego, CA focused on acquiring, marketing and developing pain and related products. Victory markets its existing pain products through its physician-based field sales force. The Company is also developing several proprietary products for treatment of chronic severe pain and commonly associated opiate-induced side effects. Its lead development product is currently near completion of Phase II clinical testing in the United States.
Naprelan® is a registered trademark of Elan Corporation, plc.
Source: Victory Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.